Pathological response according to the INMC criteria
| Pathological response . | A: IFN-γ high NIVO (n = 10) . | B: IFN-γ high NIVO + DOM BID (n = 10) . | C: IFN-γ low NIVO + DOM BID (n = 10) . | D: IFN-γ low IPI + NIVO + DOM QD (n = 10) . | D-exp: IFN-γ low IPI + NIVO + DOM BID (n = 4) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| pRR 95% confidence interval (0–50% viable tumor) | 9 | (90%) (55–99.7%) | 8 | (80%) (44–97%) | 3 | (30%) (7–65%) | 4 | (40%) (12–74%) | 2 | (50%) (7–93%) |
| pCR (0% viable tumor) | 8 | (80%) | 4 | (40%) | 1 | (10%) | 3 | (30%) | – | – |
| near-pCR (>0–10% viable tumor) | – | – | 2 | (20%) | – | – | 1 | (10%) | 1 | (25%) |
| pPR (>10–50% viable tumor) | 1 | (10%) | 2 | (20%) | 2 | (20%) | – | – | 1 | (25%) |
| pNR (>50% viable tumor) | 1 | (10%) | 2 | (20%) | 7 | (70%) | 6 | (60%) | 2 | (50%) |
| Pathological response . | A: IFN-γ high NIVO (n = 10) . | B: IFN-γ high NIVO + DOM BID (n = 10) . | C: IFN-γ low NIVO + DOM BID (n = 10) . | D: IFN-γ low IPI + NIVO + DOM QD (n = 10) . | D-exp: IFN-γ low IPI + NIVO + DOM BID (n = 4) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| pRR 95% confidence interval (0–50% viable tumor) | 9 | (90%) (55–99.7%) | 8 | (80%) (44–97%) | 3 | (30%) (7–65%) | 4 | (40%) (12–74%) | 2 | (50%) (7–93%) |
| pCR (0% viable tumor) | 8 | (80%) | 4 | (40%) | 1 | (10%) | 3 | (30%) | – | – |
| near-pCR (>0–10% viable tumor) | – | – | 2 | (20%) | – | – | 1 | (10%) | 1 | (25%) |
| pPR (>10–50% viable tumor) | 1 | (10%) | 2 | (20%) | 2 | (20%) | – | – | 1 | (25%) |
| pNR (>50% viable tumor) | 1 | (10%) | 2 | (20%) | 7 | (70%) | 6 | (60%) | 2 | (50%) |
DOM, domatinostat; IPI, ipilimumab; NIVO, nivolumab; pCR, pathological complete response; pNR, pathological non-response; pPR, pathological partial response; pRR, pathological response rate.